Jump to content

IBS Meta-Analysis Offers Some Support for Mesalamine - MDedge

Health Reporter

Recommended Posts

IBS Meta-Analysis Offers Some Support for Mesalamine  MDedge

Certain patients with irritable bowel syndrome (IBS) may benefit from treatment with mesalamine, although the quality of evidence supporting this strategy remains low, according to a recent systematic literature review and meta-analysis.

Global IBS symptoms improved significantly across the entire population, however, a subgroup analysis suggested that mesalamine may be most beneficial for patients who present with diarrhea, providing support for a large clinical trial in this patient population, reported lead author Vivek C. Goodoory, MBChB, of St. James’s University Hospital, Leeds, United Kingdom, and colleagues.

Some patients with IBS may present with low-grade inflammation in the intestine, offering theoretical grounds for prescribing mesalamine, which is typically used for treating ulcerative colitis, the investigators wrote in Clinical Gastroenterology and Hepatology. Yet previous randomized controlled trials (RCTs) evaluating mesalamine for IBS have yielded mixed results, and a meta-analysis showed that mesalamine offered no benefit.

View the full article

Link to comment
Share on other sites

  • Jeffrey Roberts changed the title to IBS Meta-Analysis Offers Some Support for Mesalamine - MDedge
  • Create New...